Duplex high‐throughput flow cytometry screen identifies two novel formylpeptide receptor family probes

Of recent, clinical interest have been two related human G‐protein coupled receptors: formylpeptide receptor (FPR), linked to antibacterial inflammation and malignant glioma cell metastasis; and FPR like‐1 (FPRL1), linked to chronic inflammation in systemic amyloidosis, Alzheimer's disease, and prion diseases. In association with the National Institutes of Health (NIH) Molecular Library Screening Network, we implemented a flow‐cytometry‐based high‐throughput screening (HTS) approach for identifying selective small molecule FPR and FPRL1 ligands. The screening assay measured the ability of test compounds to competitively displace a high‐affinity, fluorescein‐ labeled peptide ligand from FPR, FPRL1, or both. U937 cells expressing FPR and rat basophil leukemia (RBL) cells expressing FPRL1 were tested together in a “duplex” format. The U937 cells were color coded with red‐fluorescent dye allowing their distinction during analysis. Compounds, cells, and fluorescent ligand were sequentially combined (no wash) in 15 μl assay volumes in 384‐well plates. Throughput averaged ∼11 min per plate to analyze ∼4,000 cells (∼2,000/receptor) in a 2 μl aspirate from each well. In primary single concentration HTS of 24,304 NIH Small Molecule Repository compounds, 253 resulted in inhibition >30% (181 for FPR, 72 for FPRL1) of which 40 had selective binding inhibition constants (Ki) ≤ 4 μM (34 for FPR and 6 for FPRL1). An additional 1,446 candidate compounds were selected by structure–activity‐relationship analysis of the hits and screened to identify novel ligands for FPR (3570‐0208, Ki = 95 ± 10 nM) and FPRL1 (BB‐V‐115, Ki = 270 ± 51 nM). Each was a selective antagonist in calcium response assays and the most potent small molecule antagonist reported for its respective receptor to date. The duplex assay format reduced assay time, minimized reagent requirements, and provided selectivity information at every screening stage, thus proving to be an efficient means to screen for selective receptor ligand probes. © 2008 International Society for Advancement of Cytometry

[1]  W. Gong,et al.  A Seven-transmembrane, G Protein–coupled Receptor, FPRL1, Mediates the Chemotactic Activity of Serum Amyloid A for Human Phagocytic Cells , 1999, The Journal of experimental medicine.

[2]  Ji Ming Wang,et al.  Pleiotropic roles of formyl peptide receptors. , 2001, Cytokine & growth factor reviews.

[3]  Garry P Nolan,et al.  Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling , 2006, Nature Methods.

[4]  Jennifer E. Golden,et al.  Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. , 2006, Bioorganic & medicinal chemistry letters.

[5]  Bruce S Edwards,et al.  High‐throughput flow cytometry: Validation in microvolume bioassays , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[6]  P. Murphy,et al.  Impaired Antibacterial Host Defense in Mice Lacking the N-formylpeptide Receptor , 1999, The Journal of experimental medicine.

[7]  X. Bian,et al.  Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. , 2005, Journal of the National Cancer Institute.

[8]  R. Ye,et al.  Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. , 2003, Blood.

[9]  D Rodbard,et al.  An exact correction to the "Cheng-Prusoff" correction. , 1988, Journal of receptor research.

[10]  D. Haviland,et al.  N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation , 1995, The Journal of experimental medicine.

[11]  P A Ward,et al.  Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. , 1984, The Journal of biological chemistry.

[12]  R N Kalaria,et al.  Microglia and Alzheimer's disease. , 1999, Current opinion in hematology.

[13]  C. Serhan,et al.  Identification of a Human Enterocyte Lipoxin A4 Receptor That Is Regulated by Interleukin (IL)-13 and Interferon γ and Inhibits Tumor Necrosis Factor α–induced IL-8 Release , 1998, The Journal of experimental medicine.

[14]  C. Serhan,et al.  Activation of Lipoxin a4 Receptors by Aspirin-Triggered Lipoxins and Select Peptides Evokes Ligand-Specific Responses in Inflammation , 2000, The Journal of experimental medicine.

[15]  R. Ye,et al.  Erratum: Pharmacological characterization of a novel nonpeptide antagonist for formyl peptide receptor-like 1 (Molecular Pharmacology (2007) 72 (976-983)) , 2007 .

[16]  E. Prossnitz,et al.  The N-formyl peptide receptor: a model for the study of chemoattractant receptor structure and function. , 1997, Pharmacology & therapeutics.

[17]  V. Ferrans,et al.  Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled receptor FPRL1 and forms fibrillar aggregates in macrophages. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Tudor I. Oprea,et al.  Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonistss⃞ , 2005, Molecular Pharmacology.

[19]  Garry P. Nolan,et al.  Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry , 2002, Nature Biotechnology.

[20]  Chentao Lin,et al.  Formyl peptide receptor-like 1–mediated endogenous TRAIL gene expression with tumoricidal activity , 2007, Molecular Cancer Therapeutics.

[21]  V. Ferrans,et al.  The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1. , 2001, Journal of immunology.

[22]  V. Gerke,et al.  A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. , 2000, Molecular cell.

[23]  S. Whittemore,et al.  Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia , 1995, Journal of Neuroimmunology.

[24]  L A Sklar,et al.  High throughput flow cytometry. , 2001, Cytometry.

[25]  W. Gong,et al.  T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors. , 1999, Journal of immunology.

[26]  P. Murphy The molecular biology of leukocyte chemoattractant receptors. , 1994, Annual review of immunology.

[27]  Philip M Murphy,et al.  Formyl-peptide receptors revisited. , 2002, Trends in immunology.

[28]  O. C. Blair,et al.  Practical Flow Cytometry , 1985, The Yale Journal of Biology and Medicine.

[29]  R. Ye,et al.  Pharmacological Characterization of a Novel Nonpeptide Antagonist for Formyl Peptide Receptor-Like 1 , 2007, Molecular Pharmacology.

[30]  E. Prossnitz,et al.  Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. , 1992, Biochemical and biophysical research communications.

[31]  U. Francke,et al.  A structural homologue of the N-formyl peptide receptor. Characterization and chromosome mapping of a peptide chemoattractant receptor family. , 1992, The Journal of biological chemistry.

[32]  R. Eddy,et al.  Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19. , 1992, Genomics.

[33]  John P Nolan,et al.  Suspension array technology: evolution of the flat-array paradigm. , 2002, Trends in biotechnology.

[34]  Bernhard Schmidt,et al.  Role of microglia and host prion protein in neurotoxicity of a prion protein fragment , 1996, Nature.

[35]  K. Matsushima,et al.  Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. , 1993, International immunology.

[36]  X. Bian,et al.  Production of angiogenic factors by human glioblastoma cells following activation of the G-protein coupled formylpeptide receptor FPR , 2007, Journal of Neuro-Oncology.

[37]  R. Ye,et al.  A Novel Nonpeptide Ligand for Formyl Peptide Receptor-Like 1 , 2004, Molecular Pharmacology.

[38]  W. Gong,et al.  Expression of functional formyl peptide receptors by human astrocytoma cell lines , 2000, Journal of Neuroimmunology.

[39]  S. Wahl,et al.  N-formylmethionyl peptides as chemoattractants for leucocytes. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Ji Ming Wang,et al.  Ll-37, the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fprl1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells , 2000, The Journal of experimental medicine.

[41]  A. Khlebnikov,et al.  High-Throughput Screening for Small-Molecule Activators of Neutrophils: Identification of Novel N-Formyl Peptide Receptor Agonists , 2007, Molecular Pharmacology.

[42]  J. Robotham,et al.  The acute-phase response. , 1995, New horizons.

[43]  R. Ye,et al.  Identification of Novel Formyl Peptide Receptor-Like 1 Agonists That Induce Macrophage Tumor Necrosis Factor α Production , 2008, Molecular Pharmacology.

[44]  S. Su,et al.  N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes. , 2000, Clinical immunology.

[45]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[46]  P. Ward,et al.  The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. , 1975, Journal of immunology.

[47]  P. Allavena,et al.  Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. , 1995, Journal of immunology.

[48]  Tudor I. Oprea,et al.  High-Throughput Screening with HyperCyt® Flow Cytometry to Detect Small Molecule Formylpeptide Receptor Ligands , 2005, Journal of biomolecular screening.

[49]  P. Murphy,et al.  Amyloid-β Induces Chemotaxis and Oxidant Stress by Acting at Formylpeptide Receptor 2, a G Protein-coupled Receptor Expressed in Phagocytes and Brain* , 2001, The Journal of Biological Chemistry.

[50]  H. Carp Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils , 1982, The Journal of experimental medicine.

[51]  T Davies,et al.  Classification and properties of 64 multiplexed microsphere sets. , 1998, Cytometry.

[52]  W. Shen,et al.  Amyloid β42 Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1 , 2001, The Journal of Neuroscience.

[53]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  V. Ferrans,et al.  β Amyloid peptide (Aβ42) is internalized via the G‐protein‐coupled receptor FPRL1 and forms fibrillar aggregates in macrophages1 , 2001 .

[55]  K. Matsushima,et al.  Properties of the novel proinflammatory supergene "intercrine" cytokine family. , 1991, Annual review of immunology.

[56]  W. Gong,et al.  Receptors for chemotactic formyl peptides as pharmacological targets. , 2002, International immunopharmacology.